Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
Putnam Biorevolution ETF (SYNB)SYNB
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based out of last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2024: SYNB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Upturns
Type: ETF | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Profit: 7.44% | Upturn Advisory Performance  5 | Avg. Invested days: 62 |
| Profits based on simulation | ETF Returns Performance  2 | Last Close 09/18/2024 |
Type: ETF | Today’s Advisory: Consider higher Upturn Star rating |
Profit: 7.44% | Avg. Invested days: 62 |
Upturn Star Rating | ETF Returns Performance 2 |
| Profits based on simulation Last Close 09/18/2024 | Upturn Advisory Performance 5 |
Key Highlights
Volume (30-day avg) 265 | Beta - |
52 Weeks Range 24.45 - 33.00 | Updated Date 09/19/2024 |
52 Weeks Range 24.45 - 33.00 | Updated Date 09/19/2024 |
AI Summarization
Putnam BioRevolution ETF (BMED) Summary
Profile: The Putnam BioRevolution ETF (BMED) is an actively managed ETF that invests in companies positioned to benefit from advancements in the life sciences industry. This includes companies involved in biotechnology, pharmaceuticals, medical devices, and healthcare information technology.
Objective: BMED's primary investment goal is to achieve long-term capital appreciation by investing in a diversified portfolio of life sciences companies.
Issuer: Putnam Investments is the issuer of BMED. Putnam is a well-established investment management firm with over 75 years of experience and a strong reputation for managing actively managed funds.
Market Share: BMED has a market share of approximately 0.3% within the broader healthcare ETF category.
Total Net Assets: As of November 2023, BMED has approximately $1.2 billion in total net assets.
Moat: BMED's competitive advantage lies in its active management approach and experienced portfolio management team. The team leverages their deep industry knowledge and research capabilities to identify promising companies within the life sciences sector.
Financial Performance: BMED has delivered competitive returns since its inception in 2018. However, it is important to note that past performance is not indicative of future results.
Benchmark Comparison: BMED has outperformed the S&P 500 Index and the Nasdaq Biotechnology Index over the past three years.
Growth Trajectory: The life sciences industry is expected to experience continued growth in the coming years, driven by factors such as an aging population, increasing healthcare spending, and technological advancements. This bodes well for BMED's future growth prospects.
Liquidity: BMED has an average daily trading volume of approximately 200,000 shares, indicating good liquidity.
Bid-Ask Spread: The bid-ask spread for BMED is typically around 0.10%, which is considered tight and reflects good liquidity.
Market Dynamics: The life sciences industry is influenced by factors such as government regulations, scientific breakthroughs, and economic conditions. Investors should stay informed about these factors to assess potential risks and opportunities.
Competitors: BMED's key competitors include the iShares Biotechnology ETF (IBB), the SPDR S&P Biotech ETF (XBI), and the VanEck Biotech ETF (BBH).
Expense Ratio: BMED's expense ratio is 0.65%, which is slightly higher than the average for actively managed healthcare ETFs.
Investment Approach and Strategy: BMED utilizes a bottom-up stock selection process, focusing on companies with strong fundamentals, innovative products, and experienced management teams. The portfolio is diversified across various sub-sectors within the life sciences industry.
Key Points:
- Actively managed ETF focused on the life sciences industry.
- Strong track record of outperforming the market.
- Experienced portfolio management team.
- Competitive expense ratio.
- Good liquidity.
Risks:
- Volatility: The life sciences industry is subject to high volatility, which can impact BMED's performance.
- Market Risk: BMED's performance is directly tied to the performance of the life sciences industry.
- Concentration Risk: BMED invests in a concentrated portfolio of companies, which may increase its volatility.
Who Should Consider Investing: BMED is suitable for investors with a long-term investment horizon and a tolerance for risk. It is also appropriate for investors seeking exposure to the growth potential of the life sciences industry.
Fundamental Rating Based on AI:
Based on an AI-powered analysis of the factors mentioned above, BMED receives a 7 out of 10 rating. The AI model considers the ETF's strong financial performance, experienced management team, and growth potential of the life sciences industry as positive factors. However, the higher expense ratio and concentration risk are viewed as potential drawbacks.
Resources:
- Putnam BioRevolution ETF website: https://www.putnam.com/individual/etfs/etf-detail?etfId=bmed
- Yahoo Finance: https://finance.yahoo.com/quote/BMED/
Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Please consult a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Putnam Biorevolution ETF
The fund invests mainly in common stocks (growth or value stocks or both) of companies worldwide of any size with a focus on "biology revolution" companies. From time to time, the fund may invest a significant portion of its assets in companies in one or more related industries or sectors, including the health care, consumer discretionary, consumer staples, biotechnology and materials sectors. The fund is non-diversified.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.